Steven Julious
@StevenJulious
Followers
909
Following
578
Media
208
Statuses
894
Professor of Medical Statistics at The University of Sheffield and NIHR Senior Investigator. Statistician, walker and Garibaldi Red. The opinions are personal
Sheffield
Joined October 2019
Have just received the authors copy the 2nd edition of my book. Sample Sizes for Clinical Trials. It is due out 21 June . #statstwitter #epitwitter #ClinicalTrials #clinicalresearch @ScHARRSheffield @ScHARR_DTS @CTRU_Sheffield
4
27
155
Had a paper published with @Flight_LG and @Alan_Brennan entitled. Value-adaptive clinical trial designs for efficient delivery of publicly funded trials - a discussion of methods, case studies, opportunities and challenges.
0
3
3
The protocol for MissionEB - a randomised, double-blinded, placebo-controlled, two-centre, crossover trial - a study to assess mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa has been published.
0
0
0
A great talk by @JamesSalsbury at #sct2025 entitled. Assurance methods for designing a survival trial with delayed treatment effects
1
2
3
Attending an excellent talk by @NikkiTotton entitled at #SCT2025 entitled. Using benefit risk methods to adjust the non-inferiority margin based on treatment benefits
0
0
1
We recommend that the conditional frailty model be used for these data in trials, including cluster randomised trials, to help.to explain changes in event risk over time and assist clinical interpretation.
0
0
1
Had a paper published with Kelly Grant on the analysis of recurrent events in clinical trials.
1
1
7
RT @MarionKCampbell: In clinical trials it is not only potential benefits that should be measured - it is crucially important that any poteā¦.
0
11
0
RT @stats_ci: New Publication š: Trials special series - the collection, analysis and reporting of adverse events in randomised controlledā¦.
0
5
0
RT @ScHARR_MSG: Comparison of statistical methods for the analysis of patient-reported outcomes (PROs), particularly the Short-Form 36 (SF-ā¦.
0
1
0
My PhD student is undertaking a DELPHI on reporting of sample sizes with studies with adaptive designs in protocols and grants. Please fill in if you can.
This sub-study is part of a PhD project at the University of Sheffield, supervised by Prof. Steven Julious (@StevenJulious ) and Dr. Munya Dimairo (@mdimairo ).Please feel free to reach out to our team. Email: qzhang104@sheffield.ac.uk.#AdaptiveTrials #TrialDesign #SampleSize.
0
2
3
Just had a paper published led by @HollyTibble with researchers from @AUKCAR on using routine data in research.
New Paper! Routinely recorded primary care data can be used to evaluate interventions provided within routine care, anecdotally researchers in the @AUKCAR have encountered multiple barriers to access and use.
0
0
1
My paper with Amy Whitehead Mike Campbell & Cindy Cooper. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Has been cited 1000 times .
0
8
29
Nearly half of studies did not justify their non-inferiority limit
0
0
2
The paper found the use of term "non-inferioroity" increased with the publication of the CONSORT Non-inferiority Guidelines
1
0
2
Just had a paper published entitled "A review of UK publicly funded non-inferiority trials: is the design more inferior than it should be?" . Led by Nikki Totton with Stephen Walters and Elizabeth Coates.
1
4
12
The timing of the first inteim analysis between industry and publicly funded trials is quite marked. For industry studies the first interim is after 50% of the information fration. By comparison for publicly funded trials the timing is bi-modal
0
0
1
For industry studies 68% have just one interim analysis compared to 51% for publicly funded
1
0
1
Justed had paper published with @qiangzh83769692 , @mdimairo , Jen Lewis and Zihang Yu entitled . "Reporting and communication of sample size calculations in adaptive clinical trials: a review of trial protocols and grant applications".
1
7
18
The timing of the first inteim analysis between industry and publicly funded trials is quite marked. For industry studies the first interim is after 50% of the information fration. By comparison for publicly funded trials the timing is bi-modal
0
0
0